Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 21Neoplasms 7Sarcoma 4Ovarian Neoplasms 4Lung Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Neuroendocrine Tumors 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Neoplasm Metastasis 2Mesothelioma 2Desmoplastic Small Round Cell Tumor 2Colorectal Neoplasms 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × PM 01183 × Clear all
NCT05126433 2025-02-28

JAZZ EMERGE201

Jazz Pharmaceuticals

Phase 2 Terminated
47 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

AdventHealth

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡